A
1.52
0.07 (4.83%)
| Previous Close | 1.45 |
| Open | 1.44 |
| Volume | 1,576,232 |
| Avg. Volume (3M) | 2,760,648 |
| Market Cap | 165,910,240 |
| Price / Sales | 2.70 |
| Price / Book | 3.52 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -139.74% |
| Operating Margin (TTM) | -1,216.52% |
| Diluted EPS (TTM) | -1.26 |
| Quarterly Revenue Growth (YOY) | -76.90% |
| Total Debt/Equity (MRQ) | 43.39% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | -229.34 M |
| Levered Free Cash Flow (TTM) | -92.86 M |
| Return on Assets (TTM) | -17.22% |
| Return on Equity (TTM) | -90.26% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alector, Inc. | Bullish | Bullish |
AIStockmoo Score
0.3
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
|
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.61% |
| % Held by Institutions | 80.74% |
| 52 Weeks Range | ||
| Median | 5.00 (228.95%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 22 Oct 2025 | 5.00 (228.95%) | Buy | 1.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Dec 2025 | Announcement | Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer |
| 01 Dec 2025 | Announcement | Alector to Participate in the Bank of America CNS Therapeutics Conference |
| 06 Nov 2025 | Announcement | Alector Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 21 Oct 2025 | Announcement | Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |